Search
ARS Pharmaceuticals Inc
SPRYAdd to Watchlist
8.560USD
+0.620+7.81%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
850.01MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+7.81%
5 Days
-18.79%
1 Month
-9.23%
6 Months
-25.50%
Year to Date
-26.52%
1 Year
-46.80%
Key Figures
8.140Open
8.610High
1.80MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.81%Turnover Ratio
7.940Prev. Close
8.000Low
10.89MTurnover
106.28P/E Static
13.86P/B
0.00%Div Yield TTM
-64.39%ROA
18.90052wk High
0.98Volume Ratio
8.00MNet Profit
99.30MShares
-2.0023EPS TTM
0.94Beta
-136.40%ROE
6.66052wk Low
7.68%Amplitude
72.29%Gross Margin
850.01MMarket Cap
-2.34Reward/Risk
3.95%Risk Rate
TradingKey Stock Score of ARS Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
ARS Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 73 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 29.75.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ARS Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
ARS Pharmaceuticals Inc Highlights
StrengthsRisks
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 280826.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 84.28M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 84.28M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -3.97, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 96.79M shares, decreasing 8.42% quarter-over-quarter.
Held by Daniel Loeb
Star Investor Daniel Loeb holds 944.71K shares of this stock.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
29.750
Target Price
+247.55%
Upside Space
ARS Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ARS Pharmaceuticals Inc Info
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Ticker SymbolSPRY
CompanyARS Pharmaceuticals Inc
CEOLowenthal (Richard E)
Websitehttps://ars-pharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of ARS Pharmaceuticals Inc (SPRY)?
The current price of ARS Pharmaceuticals Inc (SPRY) is 7.94.
What is the symbol of ARS Pharmaceuticals Inc?
The ticker symbol of ARS Pharmaceuticals Inc is SPRY.
What is the 52-week high of ARS Pharmaceuticals Inc?
The 52-week high of ARS Pharmaceuticals Inc is 18.90.
What is the 52-week low of ARS Pharmaceuticals Inc?
The 52-week low of ARS Pharmaceuticals Inc is 6.66.
What is the market capitalization of ARS Pharmaceuticals Inc?
The market capitalization of ARS Pharmaceuticals Inc is 788.47M.
Is ARS Pharmaceuticals Inc (SPRY) currently rated as Buy, Hold, or Sell?
According to analysts, ARS Pharmaceuticals Inc (SPRY) has an overall rating of STRONG BUY, with a price target of 29.75.
What is the Earnings Per Share (EPS TTM) of ARS Pharmaceuticals Inc (SPRY)?
The Earnings Per Share (EPS TTM) of ARS Pharmaceuticals Inc (SPRY) is -1.74.